Efficacy of Ceftaroline Fosamil in a Staphylococcal Murine Pneumonia Model

Pharmacokinetics and Pulmonary Disposition of Tedizolid and Linezolid in a Murine Pneumonia Model under Variable Conditions

(2012) Rebecca A. Keel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates

(2011) Rebecca A. Keel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoEfficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae

(2011) Dora E. Wiskirchen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Affinity of Ceftaroline and Other  -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae

(2010) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Expanded Clinical Presentation of Community-Acquired Methicillin-Resistant Staphylococcus aureus Pneumonia

(2010) L. Jason Lobo et al.   CHEST

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study

(2010) R. N. Jones et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains

(2008) S. Laohavaleeson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pneumonia Caused by Methicillin‐ResistantStaphylococcus aureus

(2008) Ethan Rubinstein et al.   CLINICAL INFECTIOUS DISEASES